Action Sandoz - D8Y

Sandoz Group AG (D8Y) Action

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Dernier

78,94

( 1,31% )

Prix Achat

78,84

Prix Vente

79,04

Volume échangé

1 759

77,36 Fourchette du Jour 79,04

45,44 Plage de 52 semaines 81,08

Clôture Veille

77,92

Ouverture

77,36

Dernière Transaction

78.86

Dernière heure de transaction

Volume moyen (3 m)

2 125

Volume financier

VWAP

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations MEDIA RELEASE Sandoz signs 10-year...

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter Ad hoc announcement pursuant to art. 53 SIX Swiss...

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in...

Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach

Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market...

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million...

Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars

Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars MEDIA RELEASE Pyzchiva® first...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-0.18	-0.227502527806	79.12	81.08	76	2248	78.92172257	DE
4	9.980001	14.4721594326	68.959999	81.08	67.12	2557	75.53052894	DE
12	7.980001	11.2457738338	70.959999	81.08	64.14	2125	73.05701402	DE
26	16.16	25.7406817458	62.78	81.08	61.04	2131	70.99630458	DE
52	33.25	72.7730356752	45.69	81.08	45.44	2060	63.79976035	DE
156	39.44	99.8481012658	39.5	81.08	38.4	1983	61.46315126	DE
260	39.44	99.8481012658	39.5	81.08	38.4	1983	61.46315126	DE

D8Y - Frequently Asked Questions (FAQ)

What is the current Sandoz Group AG share price?

The current share price of Sandoz Group AG is 78,94 €

What is the 1 year trading range for Sandoz Group AG share price?

Sandoz Group AG has traded in the range of 45,44 € to 81,08 € during the past year

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Sandoz Group AG (D8Y)

Sandoz Group AG (D8Y) Action

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

D8Y Dernières nouvelles

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France

Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]

Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars

D8Y - Frequently Asked Questions (FAQ)

D8Y Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Sandoz Group AG (D8Y)

Sandoz Group AG (D8Y) Action

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

D8Y Dernières nouvelles

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France

Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]

Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars

D8Y - Frequently Asked Questions (FAQ)

D8Y Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Sign up for FREE and get:

Supprimer les publicités